Search results for "Anti her2"

showing 3 items of 3 documents

NRF2 activation via PI3K/AKT/mTOR/RPS6 causes resistance to anti-HER2 agents among HER2 amplified gastric cancer

2018

0301 basic medicinebusiness.industryCancerHematologymedicine.diseaseNrf2 activation03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCancer researchMedicineAnti her2businessProtein kinase B030217 neurology & neurosurgeryPI3K/AKT/mTOR pathwayAnnals of Oncology
researchProduct

Role of antiemetic prophylaxis for breast cancer (BC) patients treated with anti-HER2 or anti-VEGF monoclonal antibodies.

2014

e20705 Background: To date the anti-emetic prophylaxis based on the combination of 5HT3-antagonists and corticosteroids is mandatory for high and moderate emetogenic cytotoxic agents. This approach...

Anti vegfCancer Researchbusiness.industrymedicine.drug_classmedicine.diseaseMonoclonal antibodyBreast cancerOncologyCancer researchMedicineAntiemeticAnti her2CytotoxicitybusinessJournal of Clinical Oncology
researchProduct

Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-)adjuvant anti-HER2…

2013

602 Background: Addition of trastuzumab (Roche; T) to chemotherapy (CT) has improved outcomes in patients (pts) with HER2+ breast cancer at all stages, including locally advanced and metastatic disease. Anti-HER2 re-treatment with T is an increasingly used therapy option for the treatment of recurrent/metastatic breast cancer (MBC). However, limited data on T re-treatment is currently available. Methods: Patients with locally recurrent and/or MBC who received T re-therapy were included in this non-interventional study. Among 232 pts enrolled at 121 sites in Germany, 174 pts (33 locally recurrent disease, 141 MBC) were already sufficiently documented to be analyzed for efficacy of T re-ther…

OncologyCancer Researchmedicine.medical_specialtyChemotherapybusiness.industrymedicine.medical_treatmentLocally advancedNeo adjuvantmedicine.diseaseSurgeryBreast cancerOncologyTrastuzumabHER2 Positive Breast CancerInternal medicinemedicineIn patientAnti her2businessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct